Each Debenture Unit will consist of one 9.5% unsecured convertible debenture due November 2022 (the " Convertible Debentures ") of the Company, and a number of common share purchase warrants (the " Warrants ") of the Company. The total size of the Offering as well as certain other terms of the Convertible Debentures and the Warrants (including the number of Warrants per Debenture Units, the term and the exercise price) will be determined in the context of the market prior to the filing of the Prospectus Supplement. The Offering is being led on a "best-efforts" basis by Mackie Research Capital Corporation and Canaccord Genuity Corp., as co-lead agents and joint bookrunners (collectively, the " Lead Agents "), and on behalf of a syndicate of agents (together with the Lead Agents, the " Agents ").